Exosomal miR-214-3p as a potential novel biomarker for rhabdoid tumor of the kidney
link.springer.com shows its articles on its own site.
Read the article on link.springer.com ↗Article · Dec 2021 · 1 min read
In brief
In brief
This study identifies exosomal miR-214-3p as a promising biomarker for rhabdoid tumor of the kidney, a rare aggressive pediatric renal malignancy. Using miRNA sequencing and validation in cell lines and xenograft models, researchers demonstrated significantly elevated miR-214-3p levels in RTK compared to neuroblastoma and normal renal cells, offering potential for improved differential diagnosis.
Written by the GCMD Library team from the article.
Abstract
Purpose
Rhabdoid tumor of the kidney (RTK) is a rare, highly aggressive pediatric renal tumor. No specific biomarkers are available for detection of RTK, and the initial differential diagnosis from other pediatric abdominal tumors, including neuroblastoma (NB), is difficult. Exosomal miRNAs are novel cancer biomarkers that can be detected in biological fluids. We explored candidate RTK-specific exosomal miRNAs as novel biomarkers of RTK.
Methods
Exosomal miRNAs were collected from conditioned media of human RTK-derived cell lines, a human embryonic renal cell line, and human NB-derived cell lines. miRNA sequencing (miRNA-Seq) was performed to detect candidate RTK-specific exosomal miRNAs. The exosomal miRNA expression in conditioned media of tumor cell lines and serum from RTK xenograft-bearing mice was analyzed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Results
The expression of exosomal miR-214-3p detected by miRNA-Seq was highest in RTK-derived cell lines. Exosomal miR-214-3p expression level determined by qRT-PCR was significantly higher in RTK-derived cell lines than in the human embryonic renal cell line or NB-derived cell lines. Furthermore, the serum exosomal miR-214-3p expression level was significantly higher in RTK xenograft mice than controls.
Conclusion
Our data indicated that exosomal miR-214-3p has potential as a novel biomarker of RTK.